^
Association details:
| Biomarker: | EGFR negative + ALK negative + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Endostar (recombinant human endostatin) (VEGF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer: A real-world study.
Published date:
05/25/2023
Excerpt:
...we aimed to evaluate the effectiveness and safety of endostatin combined with PD-1 antibody plus chemotherapy as the first-line treatment for locally advanced or distant metastatic NSCLC with EGFR/ALK-negative….The ORR in patients who had a PD-L1 tumor proportion score (TPS) of < 1%, 1%-49%, ≥ 50%, and unknown were 50%, 50%, 75.0%, and 86.1%, respectively (p = 0.025).
Secondary therapy:
Chemotherapy + Undisclosed PD-1 inhibitor
DOI:
10.1200/JCO.2023.41.16_suppl.e20564
